Every one of those 2 sits in a single category, health-it. Salesforce is most often covered alongside Veeva Systems, which appears in 2 of these 2 stories. The 8-day window averages about 1.8 stories each week. They are less corroborated than the beat average, carrying 2 original sources each against 3.3 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Salesforce
Every one of those 2 sits in a single category, health-it. Salesforce is most often covered alongside Veeva Systems, which appears in 2 of these 2 stories. The 8-day window averages about 1.8 stories each week. They are less corroborated than the beat average, carrying 2 original sources each against 3.3 for the same window. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. We currently track 2 Healthcare stories that mention Salesforce, published between March 8, 2026 and March 15, 2026.
Stories tracked
2
Per week
1.8
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 184 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Salesforce. Shared-story counts are live from our verified record — not editorial picks.
Veeva Systems maintains a dominant position in the life sciences cloud market, serving 15 of the top 20 biopharma firms. While revenue growth has moderated to $3.2 billion, the company's $20 billion total addressable market and high switching costs position it as a resilient long-term play.
Veeva Systems is facing a wave of price target reductions from major analysts, including TD Cowen and Canaccord Genuity, reflecting caution over its platform transition. While management maintains a $6 billion revenue target for 2030, recent disclosures of competitive losses have tempered market enthusiasm.